Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
NCT00236015 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).
Conditions Studied
Interventions
- DRUG Gabitril
Study Locations (20)
California
- Valley Clinical Research — El Centro
- Radiant Research Irvine — Irvine
- Pharmacology Research Institute — Los Alamitos
- Pharmacology Research Institute — Riverside
- Clinical Innovations, Inc. — Santa Ana
Florida
- Miami Research Associates — Miami
- Medical Research Group of Central Florida — Orange City
- Clinical Neuroscience Solutions, Inc. — Orlando
- Roskamp Institute, Clinical Trials Division — Sarasota
- Stedman Clinical Trials — Tampa
Illinois
- American Medical Research — Aurora
- Henry Lahmeyer MD & Associates — Northfield
- Midwest Center for Neurobehavioral Medicine — Oakbrook Terrace
Arizona
- Pivotol Research Centers — Mesa
- Pivotal Research Center — Peoria
Colorado
- Radiant Research — Denver
Connecticut
- University of Connecticut Health Center — Farmington
Georgia
- Emory University — Atlanta
Indiana
- Indiana University Hospital AOC — Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 880 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00236015
The ClinicalTrials.gov registry entry for NCT00236015 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 880 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 17 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Anxiety Disorder appearing as the primary indexed condition, and to 1 intervention — of which Gabitril is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00236015 reports 20 study locations spanning 9 distinct geographic areas — top geographies include California, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00236015 about?
NCT00236015 is a clinical study titled "A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder". The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).
What is the current status of trial NCT00236015?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 880 participants. The study started on 2004-11. Estimated completion is 2006-03.
What conditions does trial NCT00236015 study?
This clinical trial studies the following conditions: Anxiety Disorder. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00236015?
The interventions under investigation include: Gabitril (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00236015?
This trial is sponsored by Cephalon, which has 17 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00236015 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.